Scarica l'app Stockscreener
67.44
0.64%
0.43
Dopo l'orario di chiusura:
67.63
0.19
+0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$67.01
Aprire:
$66.67
Volume 24 ore:
5.75M
Relative Volume:
0.77
Capitalizzazione di mercato:
$26.76B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-8.2787
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
-15.46%
1M Prestazione:
+35.12%
6M Prestazione:
+66.19%
1 anno Prestazione:
+105.17%
Intervallo 1D:
$65.80
$67.89
Intervallo di 1 settimana:
$65.54
$78.30
Portata 52W:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
67.44 | 26.59B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
476.31 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.12 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
859.43 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.97 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.26 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Gov't Shouldn't Face Vax Suit Targeting Moderna, Group Says - Law360
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies - Yahoo! Finance Canada
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
Moderna, Takeda and Capricor on the verge of notching big drug approvals - Pharma Voice
The mRESV-101 vaccine candidateModerna Inc. bets on RSV protection in older adults - Ad Hoc News
Jefferies Adjusts Price Target on Moderna to $60 From $53, Maintains Hold Rating - marketscreener.com
What It Means To Hold Moderna Stock In A Crash - Yahoo Finance
Weekly Recap: Moderna names Michael McDonnell to board and $950M patent payout - TradingView
Y Intercept Hong Kong Ltd Sells 444,343 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Moderna (MRNA) Stock Plunges Over 10% Amid Insider Sales and Bearish Analyst Sentiment - Blockonomi
The mRNA-1273.214 bivalent boosterModerna bets on updated Covid protection - ad-hoc-news.de
Moderna stock holds steady as mRNA pipeline and COVID booster strategy shape long-term outlook - ad-hoc-news.de
Form 4 Moderna Inc For: 10 July By Investing.com - Investing.com Nigeria
Moderna, Inc.’s Stock Price Plummets to $68.27, Witnessing a Sharp 10.83% Decline - Smartkarma
Moderna, Inc. (MRNA) grants RSUs and stock options to director Michael R. McDonnell - Stock Titan
Moderna (MRNA) files Form 3 registering director Michael R. McDonnell as insider - Stock Titan
Moderna (MRNA) Sees Significant Drop in Stock Price - GuruFocus
MRNA Stock Eyes Worst Week In 11 Months After June Surge — What’s Ahead? - Yahoo Finance
Meta, Moderna among market cap stock movers on Friday By Investing.com - Investing.com India
Meta, Moderna among market cap stock movers on Friday - Investing.com
Moderna Stock Sinks 11%; Its 24 Million-Dose EU Deal Has a No-Minimum Catch - TechStock²
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Biotech Stocks To Keep An Eye OnJuly 10th - MarketBeat
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout - Yahoo Finance
Moderna (MRNA) Sees 8.2% Decline Amid Market Fluctuations - GuruFocus
Moderna Inc Stock (MRNA) Moved Down by 8.01% on Jul 10: Facts Behind the Movement - TradingKey
Moderna secures up to 24 million RSV vaccine dose contract with Europe - Pharmaceutical Technology
QRG Capital Management Inc. Acquires New Stake in Moderna, Inc. $MRNA - MarketBeat
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? - The Motley Fool
Moderna stock stays supported as respiratory vaccine pipeline advances - AD HOC NEWS
Moderna Inc (MRNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
mRNA Therapeutics Market Size, Share, Growth, 2034 - Straits Research
Why Moderna (MRNA) Stock Is Trading Up Today - Yahoo Finance
Moderna (MRNA) Stock May Sit Above Fair Value Following Pipeline Expansion - Yahoo Finance
Moderna wins EU contract for RSV vaccine supply - Reuters
Moderna Stock Drops After Morgan Stanley Sticks To Neutral Rating Despite Lifting Price Target - TIKR.com
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026 - ACCESS Newswire
Moderna schedules July 31 results call and corporate update - Stock Titan
RBC Capital Raises its Price Target on Moderna (MRNA) - Insider Monkey
Will New Board Appointment And mRNA Flu Progress Change Moderna's (MRNA) Pipeline Diversification Narrative? - Yahoo Finance
Moderna Appoints Michael McDonnell to Board of Directors - Investing News Network
Moderna (MRNA) Settles Vaccine Patent Case With $950 Million Upfront Payment - simplywall.st
MRNA Maintained by Morgan Stanley -- Price Target Raised to $39 - GuruFocus
MRNA Stock Heads to $60 as Investors Liquidate after New Moderna Board Appointment Announcement - FXLeaders
Moderna (MRNA) Welcomes Michael McDonnell to Board of Directors - GuruFocus
Why Moderna Stock Is the S&P 500’s Big Loser Today - Barron's
Moderna appoints Michael McDonnell to board; shares retreat from 52-week high - Seeking Alpha
Moderna (MRNA) Appoints Michael McDonnell to Board of Directors - GuruFocus
Moderna Inc outlines its next phase. MRNA pivots beyond Covid vaccines - AD HOC NEWS
Moderna Strengthens Board with New Financial Director - TipRanks
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.16%
1.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):